ECHA Urges Registrants To Weigh Benefits/Risks Of REACH Authorization
This article was originally published in The Rose Sheet
Executive Summary
When all relevant factors are considered, firms may find that it’s not worth pursuing authorization for a substance of very high concern under REACH, European Chemicals Agency rep Richard Dubourg says. In any case, authorization is only temporary until an appropriate alternative presents itself.